78219-1 78219-2
Spike (B.1.617.2.1; Delta Plus Variant) (SARS-CoV-2) Pseudotyped Lentivirus (eGFP Reporter)
BPS Bioscience
DESCRIPTION
The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.617.2.1 (also known as the Delta Plus Variant) was identified in India in the spring of 2021. This variant has a number of mutations that increase morbidity and mortality and allow the virus to spread more easily and quickly than other variants.
The Spike (B.1.617.2.1 Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 B.1.617.2.1 Variant Spike (Genbank Accession #QHD43416.1 with B.1.617.2.1 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. Compared to the Delta variant (B.1.617.2), variant Delta Plus has additional mutation K417N. These pseudovirions contain the enhanced green fluorescent protein (eGFP) reporter gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be determined via eGFP fluorescence. The Spike (B.1.617.2.1 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.617.2.1 variant in a Biosafety Level 2 facility.
DETAILS
- Notes: License Disclosure: Visit bpsbioscience.com/license for the label license and other key information about this product. Troubleshooting Guide: Visit bpsbioscience.com/lentivirus-faq for detailed troubleshooting instructions. For all further questions, please email support@bpsbioscience.com.
- Format: Aqueous buffer solution
- Species: Replication Incompetent HIV
- Mutation: T19R, G142D, 156/157 DELETION, R158G, K417N, L452R, T478K, D614G, P681R, D950N
- Shiptemp: -80°C (dry ice)
- Synonyms: coronavirus, covid, covid-19, covid19, sars cov 2, sarscov2, India variant, india lenti, India mutation, India lentivirus, pseudovirus, pseudovirion, eGFP reporter, B161721, Delta plus lentivirus, Delta plus lenti, delta, 78219-1, 78219-2
- Warnings: Avoid repeated freeze/thaw cycles. Titers can drop significantly with each freeze/thaw cycle. Biosafety: None of the HIV genes (gag, pol, rev) will be expressed in the transduced cells, as they are expressed from packaging plasmids lacking the packing signal. Although the pseudotyped lentiviruses are replication-incompetent, they require the use of a Biosafety Level 2 facility. BPS recommends following all local federal, state, and institutional regulations and using all appropriate safety precautions.
- Category: Coronavirus/Lentivirus
- Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.617.2.1 (also known as the Delta Plus Variant) was identified in India in the spring of 2021. This variant has a number of mutations that increase morbidity and mortality and allow the virus to spread more easily and quickly than other variants. The Spike (B.1.617.2.1 Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 B.1.617.2.1 Variant Spike (Genbank Accession #QHD43416.1 with B.1.617.2.1 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. Compared to the Delta variant (B.1.617.2), variant Delta Plus has additional mutation K417N. These pseudovirions contain the enhanced green fluorescent protein (eGFP) reporter gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be determined via eGFP fluorescence. The Spike (B.1.617.2.1 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.617.2.1 variant in a Biosafety Level 2 facility.
- Formulation: The lentiviruses were produced from HEK293T cells. Supplied in medium containing 90% DMEM + 10% FBS.
- Supplied As: The titer will vary with each lot; the exact value is provided with each shipment.
- Unspsc Code: 41106621
- Unspsc Name: Virus mediated expression vectors or kits
- Applications: 1. Study the mechanism of viral transduction2. Screening for neutralizing antibodies that inhibit the interaction between ACE2 and the Spike protein of SARS-CoV-2 Delta Plus variant.
- Product Type: Lentivirus
- Biosafety Level: BSL-2
- Related Products: 60187, 79951, 78215, 78216
- Storage Stability: Lentiviruses are shipped with dry ice. For long term storage, it is recommended to store the virus at -80°C. Avoid repeated freeze-thaw cycles. Titers can drop significantly with each freeze-thaw cycle.
- Scientific Category: Coronavirus
- Instructions for Use: See assay protocol for detailed instructions.